Atectura Breezhaler

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Ladda ner Bipacksedel (PIL)
16-10-2023
Ladda ner Produktens egenskaper (SPC)
16-10-2023

Aktiva substanser:

indacaterol acetate, Mometasone furoate

Tillgänglig från:

Novartis Europharm Limited 

ATC-kod:

R03AK

INN (International namn):

indacaterol, mometasone

Terapeutisk grupp:

Drugs for obstructive airway diseases,

Terapiområde:

Asthma

Terapeutiska indikationer:

Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Produktsammanfattning:

Revision: 9

Bemyndigande status:

Authorised

Tillstånd datum:

2020-05-30

Bipacksedel

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 80 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 62.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 160 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 127.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 320 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 260 mcg of mometasone furoate.
Excipient(s) with known effect
Each capsule contains approximately 25 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder, hard capsule (inhalation powder).
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powder, with the
product code “IM150-80”
printed in blue above one blue bar on the body and with the product
logo printed in blue and
surrounded by two blue bars on the cap.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powd
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 80 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 62.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 160 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 127.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 320 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 260 mcg of mometasone furoate.
Excipient(s) with known effect
Each capsule contains approximately 25 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder, hard capsule (inhalation powder).
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powder, with the
product code “IM150-80”
printed in blue above one blue bar on the body and with the product
logo printed in blue and
surrounded by two blue bars on the cap.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powd
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 16-10-2023
Produktens egenskaper Produktens egenskaper bulgariska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 23-06-2020
Bipacksedel Bipacksedel spanska 16-10-2023
Produktens egenskaper Produktens egenskaper spanska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 23-06-2020
Bipacksedel Bipacksedel tjeckiska 16-10-2023
Produktens egenskaper Produktens egenskaper tjeckiska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 23-06-2020
Bipacksedel Bipacksedel danska 16-10-2023
Produktens egenskaper Produktens egenskaper danska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 23-06-2020
Bipacksedel Bipacksedel tyska 16-10-2023
Produktens egenskaper Produktens egenskaper tyska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 23-06-2020
Bipacksedel Bipacksedel estniska 16-10-2023
Produktens egenskaper Produktens egenskaper estniska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 23-06-2020
Bipacksedel Bipacksedel grekiska 16-10-2023
Produktens egenskaper Produktens egenskaper grekiska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 23-06-2020
Bipacksedel Bipacksedel franska 16-10-2023
Produktens egenskaper Produktens egenskaper franska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 23-06-2020
Bipacksedel Bipacksedel italienska 16-10-2023
Produktens egenskaper Produktens egenskaper italienska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 23-06-2020
Bipacksedel Bipacksedel lettiska 16-10-2023
Produktens egenskaper Produktens egenskaper lettiska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 23-06-2020
Bipacksedel Bipacksedel litauiska 16-10-2023
Produktens egenskaper Produktens egenskaper litauiska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 23-06-2020
Bipacksedel Bipacksedel ungerska 16-10-2023
Produktens egenskaper Produktens egenskaper ungerska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 23-06-2020
Bipacksedel Bipacksedel maltesiska 16-10-2023
Produktens egenskaper Produktens egenskaper maltesiska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 23-06-2020
Bipacksedel Bipacksedel nederländska 16-10-2023
Produktens egenskaper Produktens egenskaper nederländska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 23-06-2020
Bipacksedel Bipacksedel polska 16-10-2023
Produktens egenskaper Produktens egenskaper polska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 23-06-2020
Bipacksedel Bipacksedel portugisiska 16-10-2023
Produktens egenskaper Produktens egenskaper portugisiska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 23-06-2020
Bipacksedel Bipacksedel rumänska 16-10-2023
Produktens egenskaper Produktens egenskaper rumänska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 23-06-2020
Bipacksedel Bipacksedel slovakiska 16-10-2023
Produktens egenskaper Produktens egenskaper slovakiska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 23-06-2020
Bipacksedel Bipacksedel slovenska 16-10-2023
Produktens egenskaper Produktens egenskaper slovenska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 23-06-2020
Bipacksedel Bipacksedel finska 16-10-2023
Produktens egenskaper Produktens egenskaper finska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 23-06-2020
Bipacksedel Bipacksedel svenska 16-10-2023
Produktens egenskaper Produktens egenskaper svenska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 23-06-2020
Bipacksedel Bipacksedel norska 16-10-2023
Produktens egenskaper Produktens egenskaper norska 16-10-2023
Bipacksedel Bipacksedel isländska 16-10-2023
Produktens egenskaper Produktens egenskaper isländska 16-10-2023
Bipacksedel Bipacksedel kroatiska 16-10-2023
Produktens egenskaper Produktens egenskaper kroatiska 16-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 23-06-2020